Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China

  • By

  • Chaoyan He

  • Rongjin Zhang

  • Hua Zhang

  • Shudong Zhang

  • Shumin Wang

  • February 3, 2026

Share

  • 1

    Azygos venous pathway (AVP) status can help identify patients at high risk for massive hemorrhage during renal cell carcinoma surgeries.

  • 2

    Radical nephrectomy and tumor thrombectomy (RNTE) is a complex procedure with significant intraoperative hemorrhage risk, averaging 1900 ml blood loss.

  • 3

    Minimally invasive RNTE techniques generally result in lower blood loss compared to open procedures, but massive hemorrhage risk remains.

  • 4

    The study quantifies the compensatory state of the azygos-hemiazygos pathway to aid in preoperative surgical planning for RCC patients.

  • 5

    Understanding AVP's role in venous drainage may improve surgical outcomes by reducing intraoperative bleeding during RNTE.

Original Source(s)

Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China

  • by Chaoyan He, Rongjin Zhang, Hua Zhang, Shudong Zhang, Shumin Wang

  • February 3, 2026

Related Content

Mortality Patterns in U.S. Patients with Kidney Malignancies: A Retrospective Analysis from 1999 to 2023

Dana-Farber Research News 12.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 - 30.

  • December 15, 2025

  • 19 min
Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2alpha inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

  • by

  • June 12, 2026

  • 3 min